계명대학교 의학도서관 Repository

Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?

Metadata Downloads
Author(s)
Myung-Ju AhnByeong-Bae ParkJin Seok AhnSang We KimHeung-Tae KimJong Seog LeeJin Hyung KangJae Yong ChoHong Suk SongSe Hoon ParkChang Hak SohnSangWon ShinJin Hyuck ChoiChang-Seok KiChan Keum ParkAlison J. HolmesPasi A. JänneKeunchil Park
Keimyung Author(s)
Song, Hong Suk
Department
Dept. of Internal Medicine (내과학)
Journal Title
Clinical Cancer Research
Issued Date
2008
Volume
14
Issue
12
Abstract
Purpose: This study investigated possible molecular predictors of outcome in Korean patients
with advanced non-small cell lung cancer treated with erlotinib.
Experimental Design: One hundred and twenty patients received erlotinib and were followed
prospectively. Ninety-two tissue samples were analyzed for epidermal growth factor receptor
(EGFR) gene mutations (exons 18, 19, and 21), 88 for EGFR gene amplification by real-time
PCR, and 75 for EGFRprotein expressionby immunohistochemistry.
Results:The overall tumor response ratewas 24.2%(complete response, 4; partial response, 25)
with 56.7% of disease control rate.With a median follow-up of 23.6 months, the median time to
progression (TTP) was 2.7 months and the median overall survival was12.9 months. EGFR gene
mutations were found in 26.1% (24 of 92), EGFR gene amplification in 40.9% (36 of 88), and
EGFR protein expression in 72% (54 of 75).There was a strong association between EGFR gene
mutations and gene amplification (c = 0.241). Patients with EGFR gene mutations or gene amplification
showed both better response rate (58.3% versus 16.2%, P < 0.001; 41.7% versus 17.3%,
P = 0.012) and TTP (8.6 versus 2.5 months, P = 0.003; 5.8 versus 1.8 months, P < 0.001) and
overall survival (not reached versus 10.8 months, P = 0.023; not reached versus 10.1months,
P = 0.033). By multivariate analysis, EGFR gene mutation was the only significant molecular
predictor for TTP (hazard ratio, 0.47; 95% confidence interval, 0.25-0.89).
Conclusions: Our findings indicate that EGFR gene mutation is a more predictive marker for improved
TTP than EGFR gene amplification in erlotinib-treated Korean non-small cell lung cancer
patients. Prospective studies fromdiverse ethnic backgrounds are required to determine the exact
role of these molecular markers.
Keimyung Author(s)(Kor)
송홍석
Publisher
School of Medicine
Citation
Myung-Ju Ahn et al. (2008). Are There Any Ethnic Differences in Molecular Predictors of Erlotinib
Efficacy in Advanced Non-Small Cell Lung Cancer? Clinical Cancer Research, 14(12), 3860–3866. doi: 10.1158/1078-0432.CCR-07-4608
Type
Article
ISSN
1078-0432
DOI
10.1158/1078-0432.CCR-07-4608
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35478
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.